CVRx (CVRX) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 revenue came in at $13.8 million, below the roughly $13.94 million consensus estimate, while EPS (earnings per share) was a loss of $0.52 versus the approximately $0.50 loss analysts expected.
• Full-year 2026 revenue guidance was lowered to a range of $56 million to $57 million, down from the prior $58 million to $60 million.
• Management guided fourth-quarter 2026 revenue of $11.7 million to $12.7 million and outlined plans to reduce its baseline cost structure.
• The company confirmed a CFO transition, with John Landry succeeding Jared Oasheim effective Nov. 6, 2026.
• For additional detail, explore CVRx's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover automated market ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

CVRx is a commercial-stage medical device company focused on neuromodulation therapies for cardiovascular disease. Its flagship product, Barostim, is the first FDA (U.S. Food and Drug Administration)-approved device that uses electrical pulses to the carotid baroreceptors to help improve symptoms in patients with heart failure. Because the company remains in an investment-heavy, pre-profitability phase, quarterly earnings are closely watched as a measure of commercial execution, reimbursement progress, and cash runway. Prior quarters showed solid U.S. revenue growth, but the third quarter marked a step back, with revenue declining year over year and management trimming its full-year outlook. This report is therefore important for gauging whether the company's growth trajectory is still intact amid broader reimbursement and operational pressures.

Reported Results

For the third quarter of 2026 (the three months ended September 30, 2026), CVRx reported total revenue of $13.8 million, below the consensus estimate of roughly $13.94 million and down from $14.69 million in the prior-year period. The company posted a net loss of $0.52 per share, wider than the approximately $0.50 per-share loss analysts had expected, based on 27.2 million weighted-average shares outstanding.

Cash and cash equivalents stood at $58.7 million as of September 30, 2026. Net cash used in operating and investing activities was $11.0 million for the quarter, compared with $10.0 million in the same period a year earlier. The company also reduced its full-year 2026 revenue guidance to $56 million to $57 million from a prior range of $58 million to $60 million, while maintaining gross margin guidance of 86% to 87% and lowering operating expense guidance to $99 million to $101 million. For the fourth quarter of 2026, CVRx expects revenue between $11.7 million and $12.7 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like CVRx and the broader medical device sector, it offers a structured way to surface relevant opportunities.

Market Reaction and Investor Sentiment

Investor sentiment heading into the report was already cautious, with CVRx shares down roughly 79% year to date through early November, sharply underperforming the broader Nasdaq Composite. The third-quarter results reinforced those concerns, as revenue fell short of expectations and full-year guidance was reduced. In response, management outlined a comprehensive set of cost-reduction actions, including cuts in non-commercial functions while continuing to invest in sales and reimbursement teams, as well as disciplined hiring and a pullback on certain marketing and research and development projects. The simultaneous CFO transition adds another element for investors to evaluate as the company works to stabilize its operating model and cash position.

Forward Outlook and Key Factors to Monitor

Looking ahead, the lowered full-year guidance suggests management expects a more measured growth trajectory through the end of 2026. Investors will want to monitor whether the company can execute on its cost-reduction plan without weakening its commercial momentum in the United States, where expansion of sales territories and active implanting centers has been a key growth driver.

Reimbursement dynamics remain a central watch item. Earlier in the year, CVRx highlighted progress with the transition to Category I CPT codes (permanent, standardized medical procedure billing codes), but also noted administrative friction around Medicare Advantage prior-authorization processes. How approval rates trend in coming quarters will be important for near-term revenue.

Longer term, the BENEFIT-HF clinical trial represents a major catalyst, as a successful outcome could significantly expand the eligible patient population for Barostim. Additionally, late-breaking data from the REBALANCE Registry presented at the HFSA (Heart Failure Society of America) scientific meeting, covering 435 patients across 45 U.S. centers, underscores the company's effort to build real-world clinical evidence. The newly appointed CFO's leadership and any further updates to cash management and cost discipline will also be closely watched.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations